Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
CDtargeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma NDMM that are transplant ineligible TI and is considered the best standard of care SOC. Key secondary endpoints included response rates, MRD assessment rates, survival and safety.
At a median follow-up of The addition of weekly bortezomib did not significantly affect the relative dose intensity of IsaRd. Novel quadruplet-based strategies are needed to further deepen responses, particularly to improve the MRD negativity rate, and to prevent relapses often responsible for early deaths in this elderly population 4 , 5 , 6.
Isatuximab, an immunoglobulin Ig G1 monoclonal antibody, targets a specific epitope of human CD38, inducing myeloma cell death through multiple mechanisms 7 , 8. Several trials have demonstrated benefit by adding isatuximab to SOC backbone regimens 2 , 9. There is no report of the safety and efficacy profiles of a quadruplet-based regimen combining isatuximab with a weekly-based VRd for patients with NDMM that are TI.
A total of patients were enrolled, with assigned to either the IsaRd or Isa-VRd arm, and received at least one dose of treatment Fig. The baseline characteristics of the patients were well balanced across the study arms Table 1. The reasons for discontinuation of bortezomib are reported in Extended Data Table 1. The median relative dose intensity was Prespecified MRD subgroup analyses confirmed a consistent benefit across most subgroups, including some difficult-to-treat populations with worse prognostic factors Fig.
